Daniel Betticher
Overview
Explore the profile of Daniel Betticher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meier-Lienhard R, Suter C, Pabst T, Hitz F, Passweg J, Spertini O, et al.
Swiss Med Wkly
. 2025 Jan;
155():3885.
PMID: 39877935
Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available. Lymphoma-like regimens...
2.
Arditi C, Eicher M, Colomer-Lahiguera S, Bienvenu C, Anchisi S, Betticher D, et al.
Eur J Cancer Care (Engl)
. 2022 Sep;
31(6):e13705.
PMID: 36130722
Objectives: The objectives were to describe patients' experiences of cancer care in Switzerland and explore the variation of these experiences by type of cancer. Methods: The Swiss Cancer Patient Experiences...
3.
Frey V, Sebastian T, Barco S, Spirk D, Hayoz D, Periard D, et al.
Vasa
. 2022 Jul;
51(5):282-290.
PMID: 35774017
Catheter-based thrombus removal (CBTR) reduces the risk of moderate to severe post-thrombotic syndrome (PTS) in patients with acute iliofemoral deep vein thrombosis (IF-DVT). However, the impact of concomitant popliteal DVT...
4.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, et al.
J Thorac Cardiovasc Surg
. 2022 Jun;
164(6):1587-1602.e5.
PMID: 35688713
Objective: Surgical treatment of locally advanced non-small cell lung cancer including single or multilevel N2 remains a matter of debate. Several trials demonstrate that selected patients benefit from surgery if...
5.
Bana M, Ribi K, Peters S, Kropf-Staub S, Naf E, Zurcher-Florin S, et al.
Cancer Nurs
. 2021 Sep;
44(6):E687-E702.
PMID: 34507338
Background: The Symptom Navi Program (SNP) is a nurse-led intervention supporting basic symptom self-management for patients with any cancer diagnosis. The SNP has been accepted by patients and healthcare professionals...
6.
Rothschild S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, et al.
J Clin Oncol
. 2021 Jul;
39(26):2872-2880.
PMID: 34251873
Purpose: For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in...
7.
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, et al.
J Thorac Oncol
. 2020 Jun;
15(10):1647-1656.
PMID: 32565388
Introduction: Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid...
8.
Gerber A, Da Silva Lopes A, Szuts N, Simon M, Ribordy-Baudat V, Ebneter A, et al.
Health Sci Rep
. 2020 May;
3(2):e160.
PMID: 32405540
Background And Aims: The occurrence rate of adverse events (AEs) related to care among hospitalized oncology patients in Switzerland remains unknown. The primary objective of this study was to describe,...
9.
Zimmermann S, Dietrich P, Michielin O, Betticher D, Peters S
Rev Med Suisse
. 2020 Apr;
16(N° 691-2):819-822.
PMID: 32348043
Medical oncologists are steering a difficult course during the COVID-19 pandemic between three opposing forces : revisiting optimal standards of cancer care, facing constantly evolving shortages as some resources are...
10.
Jeker B, Farag S, Taleghani B, Novak U, Mueller B, Li Q, et al.
Bone Marrow Transplant
. 2020 Mar;
55(10):2047-2051.
PMID: 32214229
No abstract available.